Loading clinical trials...

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) | Clinical Trials | Clareo Health

Not Yet RecruitingPhase 2

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

GSK5764227 (Anti-B7H3 Antibody Drug Conjugate) Monotherapy or in Combination With Dostarlimab in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): a Multiomic Evaluation of Biomarkers of Response and Resistance (BeeHive)

NCT07408063•University Health Network, Toronto

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

GSK5764227

Dostarlimab

Locations

1

Canada

Locations (1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Key Dates

Start Date

February 2, 2026

Primary Completion Date

June 30, 2030

Completion Date

June 30, 2030

Last Updated

February 12, 2026

Related Studies

RECRUITINGPhase 2

Iparomlimab and Tuvonralimab in HNSCC

NCT07090317

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

COMPLETEDPhase 2

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

NCT04282109

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Contacts

Lillian Siu, MD

CONTACT

416-946-4501 tip@uhn.ca

Minge Xu

CONTACT

416-946-4501 minge.xu@uhn.ca

Sponsors

Lead Sponsor

University Health Network, Toronto

Collaborators

GlaxoSmithKline

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2026Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions